Summit Therapeutics EPS SMMT

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Summit Therapeutics' earnings per share was −$1.12 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.28.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.28	n/a	−$1.12
Q1 FY26	Mar 31, 2026	−$0.24	n/a	−$1.60
Q4 FY25	Dec 31, 2025	−$0.29	n/a	−$1.45
Q3 FY25	Sep 30, 2025	−$0.31	n/a	−$1.24
Q2 FY25	Jun 30, 2025	−$0.76	n/a	−$1.01
Q1 FY25	Mar 31, 2025	−$0.09	n/a	−$0.34
Q4 FY24	Dec 31, 2024	−$0.08	n/a	−$0.31
Q3 FY24	Sep 30, 2024	−$0.08	n/a	−$0.28
Q2 FY24	Jun 30, 2024	−$0.09	n/a	−$0.23
Q1 FY24	Mar 31, 2024	−$0.06	n/a	−$0.16
Q4 FY23	Dec 31, 2023	−$0.05	n/a	−$1.53
Q3 FY23	Sep 30, 2023	−$0.03	n/a	−$1.55

Companies in Drug Manufacturers - General nearest Summit Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
SMMTSummit Therapeutics	−$1.12
JAZZJazz Pharmaceuticals	$14.62
BMRNBiomarin Pharmaceutical	$0.37	−89% a year
CORTCorcept Therapeutics	$0.42	−63% a year
PTGXProtagonist Therapeutics	$1.03	+47% a year
TGTXTG Therapeutics	$2.74	+641% a year
ALKSAlkermes plc.	$0.38	−82% a year
AMRXAmneal Pharmaceuticals	$0.49	+4800% a year
LGNDLigand Pharmaceuticals	$9.40
KNSAKiniksa Pharmaceuticals International	$0.97	+2325% a year
BIIBBiogen	$5.65	−46% a year
Peer median	$1.00